Document Detail


Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.
MedLine Citation:
PMID:  16638738     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To investigate the influence of food and administration of an antacid (aluminum-magnesium hydroxide) or ranitidine on the absorption of BAY 59-7939 (rivaroxaban), 4 randomized studies were performed in healthy male subjects. In 2 food interaction studies, subjects received BAY 59-7939, either as two 5-mg tablets (fasted and fed), four 5-mg tablets (fasted), or one 20-mg tablet (fasted and fed). In 2 drug interaction studies, BAY 59-7939 (six 5-mg tablets) was given alone or with ranitidine (150 mg twice daily, preceded by a 3-day pretreatment phase) or antacid (10 mL). Plasma samples were obtained to assess pharmacokinetic and pharmacodynamic parameters of BAY 59-7939. In the presence of food, time to maximum concentration (t(max)) was delayed by 1.25 hours; maximum concentration (C(max)) and area under the curve (AUC) were increased, with reduced interindividual variability at higher doses of BAY 59-7939. Compared with baseline, BAY 59-7939 resulted in a relative increase in maximum prothrombin time (PT) prolongation of 44% (10 mg) and 53% (20 mg) in the fasted state, compared with 53% and 83% after food. Time to maximum PT prolongation was delayed by 0.5 to 1.5 hours after food, with no relevant influence of food type. No significant difference in C(max) and AUC was observed with coadministration of BAY 59-7939 and ranitidine or antacid.
Authors:
Dagmar Kubitza; Michael Becka; Michael Zuehlsdorf; Wolfgang Mueck
Related Documents :
19035558 - The influence of postharvest processing and storage of foodstuffs on the bioavailabilit...
15639678 - Fast-food habits, weight gain, and insulin resistance (the cardia study): 15-year prosp...
21558318 - Maternal nutrient restriction during late gestation and early postnatal growth in sheep...
11352438 - Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in h...
17066908 - Detection of viable enterohemorrhagic escherichia coli o157 using the combination of im...
24344958 - Habitat use and locomotion of the françois' langur (trachypithecus francoisi) in limes...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of clinical pharmacology     Volume:  46     ISSN:  0091-2700     ISO Abbreviation:  J Clin Pharmacol     Publication Date:  2006 May 
Date Detail:
Created Date:  2006-04-26     Completed Date:  2006-12-12     Revised Date:  2009-11-02    
Medline Journal Info:
Nlm Unique ID:  0366372     Medline TA:  J Clin Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  549-58     Citation Subset:  IM    
Affiliation:
Institute of Clinical Pharmacology, Bayer HealthCare AG, Wuppertal, Germany. dagmar.kubitza@bayerhealthcare.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aluminum Hydroxide / pharmacology
Antacids / pharmacology*
Cross-Over Studies
Dietary Carbohydrates / pharmacology
Dietary Fats / pharmacology
Drug Combinations
Drug Interactions
Factor Xa / antagonists & inhibitors
Fasting / metabolism
Food-Drug Interactions*
Histamine H2 Antagonists / pharmacology
Humans
Intestinal Absorption / drug effects
Magnesium Hydroxide / pharmacology
Male
Morpholines / adverse effects,  blood,  pharmacokinetics*,  pharmacology
Prothrombin Time
Ranitidine / pharmacology*
Thiophenes / adverse effects,  blood,  pharmacokinetics*,  pharmacology
Chemical
Reg. No./Substance:
0/Antacids; 0/Dietary Carbohydrates; 0/Dietary Fats; 0/Drug Combinations; 0/Histamine H2 Antagonists; 0/Morpholines; 0/Thiophenes; 0/rivaroxaban; 1309-42-8/Magnesium Hydroxide; 21645-51-2/Aluminum Hydroxide; 37317-08-1/aluminum hydroxide, magnesium hydroxide, drug combination; 66357-35-5/Ranitidine; EC 3.4.21.6/Factor Xa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Development of a predictive pharmacokinetic model for a novel cyclooxygenase-2 inhibitor.
Next Document:  Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in health...